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Abstract 
Abstract 
Prostate cancer (PCa) is the second most common cancer among the male population. 
Conventional therapies target androgen signalling, which drives tumour growth, however, 
they provide limited survival benefits for patients. It is essential, therefore, to develop a more 
specific biomarker than the current gold standard, PSA testing. The Wnt signalling pathway 
induces expression of target genes through cell surface receptors. A non-canonical member of 
this family, Wnt-11, is evolutionarily highly conserved and is normally expressed by various 
cells in the developing embryo, as well as in the heart, liver and skeletal muscle of adult 
humans. We comprehensively review several cell signalling pathways to explain how they 
interact with Wnt-11, demonstrating its use as a potential biomarker for PCa. Several studies 
have shown that the expression of Wnt-11 is associated with gastric, renal and colorectal 
adenocarcinomas and PCa. Moreover, Wnt-11 affects extracellular matrix composition and 
cytoskeletal rearrangement, and it is required for proliferation and/or survival during cell 
differentiation. It was found that PCa cell lines express high levels of Wnt-11, which allows 
differentiation of the epithelial prostate tumour cells to neuron-like (NE) cells. The NE cells 
produce additional factors that can cause regression after treatment. Accumulating evidence 
shows that Wnt-11 could be a potential biomarker in diagnosing PCa. Many studies have 
shown both non-canonical and canonical Wnts interact with several signalling cascades such 
as PKC, JNK, NFκB, Rho, PKA and PI3K. In particular, evidence demonstrates Wnt-11 is 
involved in the progression of PCa, thus it could have the potential to become both a specific 
disease marker and an important therapeutic target. 
 
 
 
 
Key words: Wnt-11, prostate cancer, cell signalling  
Introduction 
Prostate cancer (PCa) remains a major health risk for men, especially over the age of 65, with 
the annual death rate in the western world reaching more than 100,000 cases [1] . Issues 
surrounding detection, management and prevention of PCa have driven debate amongst 
scientists worldwide. The main objective for current PCa researchers is to define treatment 
options that are successful for both localised and metastatic disease.  
Legalisation of the prostate specific antigen (PSA) test within the UK still remains in 
question. According to the U.S. Food and Drug Administration, 4.0 ng/ml is described as the 
upper limit of PSA for PCa [2]. An increased PSA level can be indicative of PCa, but can 
also be linked to benign prostatic hyperplasia, urinary tract infections and prostatitis. This 
leads to the assumption that the PSA test is more sensitive than specific. On the other hand, 
the PSA test can neglect PCa diagnosis and cannot distinguish between aggressive and the 
non-aggressive form  [3]. In a modified approach, the PSA test includes monitoring the PSA 
levels over a period of time. This is defined as PSA velocity, which is the change in PSA 
levels per year (ng/ml/year) [4]. This highlights the need for more reliable biomarkers to 
generate more efficient and effective methods to screen and monitor the progression of PCa. 
An example of a biomarker that has been well characterized in PCa is a chromosomal 
rearrangement, namely the TMPRSS2-ERG gene fusion  [5]. The TMPRSS2 gene is an 
androgen responsive promoter, which, when fused with the transcriptional factor from the 
ETS family, can drive tumour progression under androgen influences. This gene fusion was 
present in 79% of 29 PCa cases. However, whilst this biomarker has shown a statistically 
significant correlation with PCa, the time at which is presents itself it still unclear [3] . 
This review will focus on the role Wnt signalling in the onset of PCa, its progression, and its 
malignancy, in the hope that Wnt could be a candidate as a biomarker in PCa diagnosis. In 
particular the focus will be on Wnt-11 and the mechanism of its downstream signal 
transduction cascades and their interactions with one another, and whether the inhibition of 
certain pathways will decrease cellular proliferation, migration and invasion of cancerous 
cells.   
Wnt proteins and their functions 
The Wnt signalling pathway was first described during a study into colon cancer, and also in 
embryonic developmental studies of Drosophilia  [6].  Embryogenesis and adult homeostasis 
are just two of many functions of the Wnt proteins  [7]. However, when aberrant Wnt 
signalling occurs, tumourgenesis can arise such as PCa. Two Wnt signalling pathways have 
been identified: canonical and non-canonical pathways. A hallmark of the canonical pathway 
is the activation and stabilisation of a signalling pool of β-catenin that acts as a transcriptional 
factor for many cancer genes in the nucleus by binding to a number of transcriptional factors 
(Figure 1), but is also involved in cadherin medicated cell adhesion [8]. The regulation of β-
catenin gene expression is mediated by interaction with both T-cell specific transcriptional 
factor and lymphoid enhancing binding factor -1 (TCF/LEF-1), both members of the 
transcriptional factor family. In the absence of Wnt signalling, a low level of β-catenin in the 
cell is maintained by ubiquitination and degradation by the destruction complex. The 
destruction complex is comprised of adenomatous polyposis coli protein (APC), glycogen 
synthase kinase 3 β (GSK3β), casein kinase 1 α, and the axin proteins [7]. However, when 
initiation of Wnt signalling occurs, Wnt interacts with the frizzled receptor, and 
phosphorylation of the low-density lipoprotein receptor related protein (LRP) occurs 
simultaneously, allowing interaction with the destruction complex. Thus accumulation of β-
catenin occurs  [7]. The non-canonical pathway involves initiation of other signalling 
cascades such as the planar cell polarity pathway and activation of Ca
2+
 (Figure 2) [9]. In 
some cases, non-canonical pathways can antagonise the canonical pathway. The non-
canonical pathway is less defined than its canonical counterpart, however it has been said that 
the frizzled receptor (Fz) can activate enzymatic cascades such as c-Jun N-terminal kinase 
(JNK), p38 and protein kinase C (PKC) [10]. The more clearly defined non-canonical 
signalling pathway is that for Wnt/planar cell polarity signalling. Wnt-11 interaction with the 
frizzled receptor can activate dishevelled (Dvl), which is a cytoplasmic scaffold protein in the 
plasma membrane. This causes downstream signalling to occur, which activates different 
features of cytoskeletal reorganisation in cell movement and polarity. For example Daam1 
and RhoA are activated, which can lead to the activation of JNK [9].
 Invasive behaviour of PCa cells is thought to be the cause of the Wnt/β-catenin signalling 
activation, which allows PCa cells to proliferate, differentiate and has an effect on the 
epithelial mesenchymal transition. Usually, malignant PCa is androgen dependent and 
androgen ablation therapy can be successful until androgen independence occurs. The 
majority of androgen-independent tumours still express the androgen receptor and it is this 
abnormal androgen receptor signalling that allows tumour progression [11].  
Wnt-11 and PCa 
Wnt-11 is one of the 19 known Wnt proteins and belongs to the non-canonical signalling 
pathway. Previously, high Wnt-11 expression in androgen-independent PCa cells and in high 
grade prostate tumours was identified [12] . Furthermore, inhibition of the androgen receptor 
and Wnt-11 signalling was found to be defective in the hormone independent PCa cell line 
PC-3. Numerous Wnt genes have been found to be expressed in both normal prostate and 
cancerous prostate cells indicating that these genes play a role in ‘house-keeping’ within the 
prostate [13]. However it has been said that expression of Wnt-11 alone is not sufficient to 
progress PCa cells to androgen-independence and therefore other aberrations accompanying 
Wnt-11 expression are needed for this phenomenon to occur. Numerous theories surround the 
fact that Wnt-11 expression is increased in androgen depleted LNCaP cells. This could be 
owing to the possibility that Wnt-11 might take part in the termination of cell growth 
following androgen depletion resulting from a signal produced by Wnt-11 [13]. Another 
theory is that the increase in Wnt-11 expression in androgen depleted LNCaP cells is due to 
neuroendocrine differentiation (NED). Neuroendocrine cells constitute a population of cells 
found in the epithelial compartment of the prostate gland. They are able to secrete factors to 
stimulate the survival and metastatic potential of cancerous prostate cells, such as neurone 
specific enolase (NSE) [14, 15]. 
The function of Wnt-11 in the onset of NED has been shown to be restricted only to PCa cells 
[15] as the ectopic expression of Wnt-11 in the RWPE-1 cell line, which is non-tumorigenic 
and exhibits characteristics similar to prostate progenitor cells, did not induce any 
neuroendocrine differentiation. To summarise, Wnt-11 is involved in progression of PCa 
cells, migration into surrounding tissues, and differentiation of these cells in neuroendocrine-
like cells. 
 Wnt and Protein kinase C (PKC) Signalling Pathways 
The protein kinase C (PKC) family of isozymes plays a vital role in cellular functions by 
transducing signals resultant from the hydrolysis of phospholipids mediated through cell 
membrane receptors. Cell membranes provide the stage for PKC to carry out its function, 
allowing the phosphorylation of PKC and its activation by binding specific lipids. These are 
tightly controlled mechanisms that regulate the production of PKC signalling within the cell. 
Often it is these mechanisms that are deregulated during the onset of cancer [16]. 
The interaction of PKC and Wnt has been well documented. When the Wnt ligand binds to 
the Fz receptor there is a sudden increase in the concentration of intracellular signalling 
molecules such as inositol 1,4,5-triphosphate (IP3), 1,2 diacylglycerol (DAG), and Ca
2+
 [17]. 
Both IP3 and DAG result from the action of phospholipase C on the membrane bound 
phospholipid phosphatidyl inositol 4,5-bisphosphate. This in turn leads to the diffusion of IP3 
through the cytosol towards the endoplasmic reticulum where calcium channels are found, 
causing a release of calcium ions. Both DAG and calcium ions activate two calcium sensitive 
proteins, PKC and calmodulin dependent kinase II (CamKII), that then activate nuclear 
transcription factors such as NFAT, NFκB and CREB that transcribe for downstream 
regulatory genes [17]. 
According to [18] PKCδ is essential for convergent extension through the function of 
disheveled (Dvl) during the Wnt/JNK signalling pathway. Further, experiments have 
confirmed that over-expression of the Fz7 receptor in Xenopus embryos caused the activation 
of PKCδ by it moving to the plasma membrane. On the other hand, reduction in PKCδ 
stopped the activation of JNK downstream of the Wnt/JNK pathway. 
PKC is one of the main components of the non-canonical pathway involved in Wnt/Ca
2+
 
signalling and has been found to take part in promoting invasiveness and malignancy in 
human cancers [7].  Using small hairpin RNA to disorder individual PKC isozymes, both in 
vitro and in vivo experiments demonstrated that, depending on cell types and signalling 
pathways, PKC isozymes are either pro-apoptotic or anti-apoptotic. It is noted that tumour 
cells display an altered balance in PKC isozyme expression. For example PKCϵ has been 
seen to be elevated in high grade prostate tumours and is involved in the progression of the 
tumour and the transition from an androgen dependent state to an androgen independent state 
in LNCaP cells [17]. Interestingly, activation of JNK downstream of TNFα was increased in 
PKCϵ depleted cells, whereas over-expression of PKCϵ decreased JNK activation, suggesting 
some interlinking of the two pathways. Therefore pharmacological targeting of PKCϵ within 
prostate tumours, where PKCϵ is overexpressed, can be a potential treatment [18]. 
Although numerous findings have shown cross talk between PKC and Wnt, their molecular 
function in cancer progression still needs to be elucidated. Screening of PKC isoforms led to 
the identification of Xenopus PKCδ as a therapeutic target for the inhibition of cancer growth 
[18].This introduces further complications as different isoforms of PKC can exert either 
overlapping or differing functions within the cell, causing issues in anti-cancer therapy. 
Therefore, it is of immense importance to address the different isoforms of PKC and their 
interactions with Wnt within mitogenesis, transformation and metastasis.  
Wnt and c-jun N-terminal kinases (JNKs)  
c-jun N-terminal kinases (JNKs) are members of the mitogen activated protein kinases 
(MAPKs) family. MAPKs can activate a variety of processes including cellular proliferation, 
tumourgenesis, differentiation and apoptosis [19]. JNK’s mode of action is to phosphorylate 
serine 63 and 73 at the N-terminal domain of c-jun. This in turn stimulates activator protein-1 
(AP-1) that then carries out transcriptional activity (Figure 3). c-jun is essential for the 
transition of the G1 phase to the remainder of the cell cycle [20]. It also carries out a 
protective role against UV induced apoptosis. At present there are only three distinct spliced 
JNK genes, JNK1, JNK2 and JNK3 
21
. JNK3 is primarily expressed throughout the nervous 
system, as opposed to JNK1 and JNK2 that are ubiquitously expressed. JNKs become 
activated during cellular stress due to exposure to UV, hypoxia, osmotic pressure, and 
variation in cytokines and growth factors concentrations [20]. Moreover, JNKs are found to 
play a role in the inflammatory signalling network, therefore, not surprisingly, the hyper-
activation of JNKs is associated with oncogenic transformation. 
Reports indicate that less than an hour of JNKs activation is linked to cell survival, whereas a 
more sustained activation of JNKs causes pro-apoptotic signalling. Moreover JNK 
participates in mRNA stabilization, cell migration, and integrity of the cell skeleton [20]. 
Members of the JNK family are robustly involved in the regulation of certain transcriptional 
factors such as ATF2, stat3, c-myc, and members of the Bcl-2 family. There is gathering 
evidence to show that JNK is involved in carcinogenesis; also, blocking JNK signalling with 
small molecule JNK inhibitors can be beneficial in the treatment of cancer. TGFβ-1 has been 
identified as a key activator of JNK1, which in turn phosphorylates p21, a cell cycle 
regulator, and up-regulates its stability through a SMAD independent mechanism [21]. 
In PCa, the administration of antisense oligonucleotide caused a defeat in PC3 PCa 
xenografts, highlighting that JNK is needed for PCa cell proliferation [22]. Moreover, the 
nuclear and total JNK expression is amplified in malignant human PCa as opposed to the 
normal epithelium. The current therapy for androgen dependent PCa, androgen ablation, may 
provoke apoptosis through JNK signalling through the production of reactive oxidative 
species in PCa cells, highlighting JNKs pro-apoptotic function. With regards to JNKs anti-
apoptotic function, JNK can protect PCa cells from apoptosis. Moreover, there is evidence 
that JNK promotes PCa metastasis by controlling cell adhesion through increasing the 
expression of extracellular matrix degradation proteins such as matrix metalloproteinases 2 
and 9 [23].  
 
Wnt and NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) 
crosstalk 
There is gathering evidence to suggest that NF-κB has a key function in tumour progression 
and chemotherapy resistance. Its function is to regulate numerous cytokines such as TNF-α, 
IL-8 and IL-1, cell adhesion molecules such as VCAM, and cell cycle genes such as c-myc 
and p53[24].  
The association of Wnt with NF-κB has been shown in osteoclasts, where an accumulation of 
nuclear β-catenin regulates the DNA binding activity of NF-κB  [25]. Moreover, according to 
[26], NF-κB is also a target of Wnt10B in U20S osteosarcoma cells. Interestingly, it has also 
been shown that NF-κB can regulate gene expression involved in cell motility and 
invasiveness, an example being MMP-9.  
The activation of NF-κB can take two pathways: classical or alternative. The classical 
pathway is triggered by either viral or bacterial infections whereas the alternative is activated 
by the members of the tumour necrosis factor family, [27]. It has been reported that the 
isoform PKCϵ mediates the activation of NF-κB in PCa cell lines and there is an established 
correlation with the over-expression of PKCϵ and the constant activation of NF-κB within 
these PCa cells. A transgenic PCa mouse model of PKCϵ over-expression triggered pre-
neoplastic lesions that exhibited noteworthy hyper-activation of NF-κB. With the use of 
interfering RNA (RNAi) targeting PKCϵ, the translocation of NF-κB to the nucleus was 
consequently depleted, impairing NF-κB transcription. Furthermore PKCϵ aids the assembly 
of the tumour necrosis receptor -1 signalling complex, which in turn activates NF-κB. Studies 
carried out by[17], demonstrated a molecular link between NF-κB and PKCϵ which plays a 
pivotal role in PCa progression. On another note, the link between NF-κB expression and 
AP-1 in PCa cells may have something to do with the differences in sensitivity to TNF-
induced apoptosis in PCa cell lines. To investigate, two cell lines were used; androgen 
dependent LNCaP, and androgen independent DU145. Results indicated that Du145 cells 
always expressed the active form of NF-κB and AP-1 and thus were resistant to TNF induced 
apoptosis. LNCaP cells were seen not to express NF-κB and therefore were susceptible to 
TNF induced apoptosis, [17].  
  
Wnt and Protein kinase A (PKA)  
Recent studies demonstrated that the progression from AR dependent to the AR independent 
form of prostate cancer is linked with increased NE expression [15]. NE cells are derived 
from non-NE PCa cells and secrete factors and peptides such as bombesin, vasoactive 
intestinal polypeptide, somatostatin, and neurotensin, which can stimulate AR independent 
growth and trigger invasion of PCa cells [14]. The cAMP (Cyclic adenosine 
monophosphate)-dependent protein kinase A (PKA) and its activator cyclic adenosine 
monophosphate (cAMP) is a classic example of a signal transduction pathway. The cAMP 
signalling pathway also interlinks with other intracellular signalling such as Ca
2+
 and Ras 
mediated MAP kinase. During pathological conditions such as PCa, the composition of the 
PKA holoenzyme, or its localisation within the cell, may change, prompting abnormal 
effects. The inactive holoenzyme is composed of a regulatory subunit (R) dimer and two 
catalytic kinase subunits (C). The active site of the C subunit reversibly associates with the 
inhibitory domain of the R subunit. Cooperative binding of cAMP molecules to the four 
nucleotide binding sites on the R subunit dimer causes dissociation of the C subunits and, 
thus, activation of the enzyme [28]. In mammalian cells, full activation of PKA requires 
phosphorylation at Thr197 by phosphoinositide-dependent protein kinase 1 (PDK1). Two 
major isoforms of PKA have been identified (PKA-I and II), and it has been shown that they 
interact with identical C subunits but have different R subunits. Several studies have shown 
that changes in the PKA-I/PKA-II ratios play a role in important processes like cellular 
differentiation and cancer development [29]. PKA-I over expression has been studied in 
various cancer cells including PCa [30]. Moreover, phase III randomized clinical trial studies 
examined PKA RIα, one of the four R subunit genes, as a biomarker to predict the outcome 
for men with locally advanced prostate cancer treated with either radiation therapy (RT) 
alone, or in addition to short-term androgen deprivation therapy (STAD) [31]. As a result, 
PKA RIα over-expression was significantly related to poor patient outcome, and observed in 
80 of 456 eligible and analysable men (17.5%). Another study of independent patients treated 
with RT and either STAD or long-term androgen deprivation therapy (LTAD) was performed 
[31]. Once again, high level of PKA RIα expression was found to be an independent predictor 
for both distant metastasis and biochemical failure. These studies confirmed that PKA can be 
a suitable marker for PCa and that there is a link between AR dependency and PKA 
signalling. Indeed, another study showed a novel mechanism for PKA and AR crosstalk and 
suggested that PKA activation can trigger AR-dependent transcription [32]. cAMP 
responsive element-binding protein (CREB) can cooperate with AR via CREB-binding 
protein (CBP) and p300. Several studies have demonstrated that increased levels of cAMP 
alone is sufficient to induce NE differentiation in both androgen-dependent and androgen-
independent cells [33]. Moreover, the NE phenotype of PCa cells can be reversible depending 
on the tumour microenvironment [34]. We have previously shown that Wnt-11 is linked to 
NE differentiation of PCa and it is PKA dependent [15], and have also observed a link 
between high level of Wnt-11 expression and CREB activity by performing CREB luciferase 
assay (unpublished results). It has been found that the cAMP pathway is concurrent with Ras 
activation through a negative feedback loop involving phosphorylation of 
phosphodiesterases, which diminishes cAMP concentrations within cells [35]. Wnt/β-catenin 
signalling has also been identified in PKA activated samples of kidney cells [36]. Taking 
these together, Wnt-11 plays a crucial role in NED of PCa by activating the cAMP/PKA 
pathway. Therefore, blocking both PKA and Wnt-11 can be potential therapy for PCa.  
Wnt and Rho family of GTPases 
The family of Rho proteins regulate the transition between an active GTP bound and an 
inactive GDP bound conformations. Rho GTPase family members control cell adhesion and 
motility via actin cytoskeleton reorganization and therefore influence a broad range of 
processes such as cell movement and cell polarity [37, 38]. Rho and Rac are the most studied 
members of this family with Rho regulating the assembly of actin and myosin filaments while 
Rac initiates actin polymerisation at the periphery of the cell [10]. Studies show that Rho 
GTPase expression levels are often significantly different in tumours and metastases and this 
correlates with a poor prognosis [39, 40]. RhoB is closely linked with both RhoA and C, and 
despite the high homology between their sequences, it has been demonstrated that RhoB 
regulates growth factor tyrosine kinase receptors’ cellular trafficking from endosomes to the 
cell membrane [41]. RhoB often acts as a tumour suppressor in cancer and regulates 
apoptosis [42]. Moreover, reduced expression of RhoB has been reported in several 
carcinomas including PCa [43]. Inhibition of RhoB expression resulted in a higher migration 
rate of PC cell line PC-3 and mouse macrophages [38, 44]. Another study demonstrated that 
RhoB is responsible for the maintenance of cell-cell junctions in epithelial PCa cell line 
DU145 in addition to controlling the N-cadherin levels of mesenchymal-like PC-3 cells [45]. 
Rho-GTPases are ideally positioned for non-canonical signalling such as the polarised 
reorganisation of the actin cytoskeleton leading to cell movement. One of the best models 
giving genetic evidence for Rho GTPase participation in non-canonical Wnt signalling is in 
the organisation of the Drosophila wing. In the wing, activation of the frizzled receptor 
results in localised Rho activation. In parallel to this, Rac activation by either frizzled or 
dishevelled causes JNK activation initiating gene expression [10].  
Wnt and PI3K 
The phosphoinositide 3-kinase (PI3K) pathway has a fundamental role in the initiation of 
numerous malignancies and their progression. The initial signalling is activated by either 
tyrosine kinase receptors’ or non-tyrosine kinase receptors’ interaction with a ligand, which 
then goes on to engage with PI3K. PI3K then proceeds to convert phosphatidylinositol (4,5)-
bisphosphate, which is membrane bound, to phosphatidylinositol (3,5)-bisphosphate. This in 
turn activates and phosphorylates Akt and then the activated Akt translocates to the 
cytoplasm and nucleus, activating downstream targets [46]. Akt has a multi-functional 
purpose in promoting cell survival by regulating pathways that take part in the cell cycle, 
resistance to apoptosis, and interaction with a host of proteins including GSK3 and mTOR. 
The latter is a serine threonine kinase that is involved in cellular proliferation and cell growth 
[47]. There are two known functional complexes of mTOR: mTOR1 and mTOR2. mTOR1 is 
rapamycin sensitive whereas mTOR2 is not. PTEN (phosphatases and tensin homolog), a 
tumour suppressor gene, is an obligate negative regulator of the PI3K/AKT/mTOR signalling 
pathway and is a crucial therapeutic target for cancers where signalling cascades are out of 
control.  
Deregulation of this pathway can arise through a series of events These include loss of 
function of PTEN through mutation, gene deletion or epigenetic silencing or mutation of 
AKT/PKB [46]. It has been shown that PTEN null cells continuously express high level of 
AKT. PCa cell lines PC-3 and LNCaP have deletions and mutations of PTEN but they have 
high levels of phosphorylated AKT in both basal and activated forms [48]. AKT regulates 
cell growth and cell survival by inactivating its downstream factors such as GSK3. In 42% of 
primary prostate tumours, mutation of the PI3K/AKT/mTOR signalling pathway, and its 
altered expression, has been reported [49]. Androgens have been reported to cause the 
accumulation of mammalian target for rapamycin complex 2 (mTORC2) complex 
components and stress activated protein kinase interacting protein-1 with in the nucleus. This 
promotes the activation of AKT by TORC2 components. The loss of both AKT and PTEN is 
correlated with a poor clinical outcome for PCa patients, generating resistance to both 
chemotherapy and radiotherapy. Moreover, loss of PTEN is associated with raised AKT 
phosphorylation, and a higher Gleason grade. This can also promote castration-resistant 
growth and a shorter time for metastasis to occur. Furthermore, preclinical studies of the 
PI3K/AKT/mTOR pathway have highlighted its importance in maintaining the cancer stem 
cell population and promotion of the transition of PCa cells from the epithelium to the 
mesenchymal [49].It was shown that blocking PI3K leads to inhibition of Wnt signalling via 
Wnt5a and Wnt3 in PCa [50]. One of the most important breakthroughs in PCa was the 
identification that ETS gene rearrangement has been reported in 50-70% of PCa cases [50]. 
PTEN loss was associated with TMPRSS2-ERG activation as nearly 40% of reported cases 
were linked[51]. PI3K pathway inhibitory complementary therapies are currently in use as 
ERG targeted therapies and this implies that PTEN loss and ETS gene rearrangements 
together may trigger downstream transcription targets to induce proliferation and cell 
survival. We believe Wnt-11 cross talks with PI3K to regulate those downstream targets as 
we found inhibition of PI3K and/or mTOR reduces Wnt11 dependent migration/invasion of 
PCa cell lines (unpublished results).  
 
Conclusion 
PCa is surrounded with dangers that implicate both patients and the healthcare system. Wnt-
11 has been evidenced to play a role in the progression, differentiation and hormone 
independent characteristics associated with malignant PCa. The PI3K/AKT/mTOR pathway 
interacts with other signalling cascades such as androgen receptor signalling and 
RAS/RAF/MEK signalling. Human epidermal growth factor 2/3 kinases (HER2/3) inhibit 
androgen receptor signalling through the PI3K/AKT/mTOR pathway via a negative feedback 
system. Moreover, PTEN can enhance AR activity by supressing the transcription of c-jun 
and Egr1, which inhibit AR transcription [50]. These suggest that PCa cells can survive in 
androgen-deprived conditions due to PTEN loss or the activation of the 
PI3K/AKT/mTOR/Wnt pathways through targeted inhibition of the AR signalling. The rarity 
of possessing the aggressive form of PCa, and its inability to be successfully treated with 
androgen ablation, still remains a big problem. Therefore the involvement of Wnt-11 and its 
interaction with various signalling pathways such as JNK, PKA and PI3K may propose 
innovative and novel research directions. This will open up new treatment options to improve 
prognosis and overall survival rate, especially for PCa.  
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Figure Legend 
Figure 1: The Wnt canonical pathway. Wnt binding to the fz receptor causing the 
dissociation of the destruction complex (axin, APC, Dsh, GSK3) causing an accumulation of 
β-catenin that is able to transport to the nucleus and transcribe for Wnt associated genes.  
Image adapted from [52]  
Figure 2:  The non-canonical pathway can take two paths. (A): The planar cell polarity 
pathway causing actin cytoskeletal rearrangements. (B): The Wnt-Ca
2+ 
pathway activating the 
calcium sensitive protein PKC.  Image adapted from [53]. 
 
Figure 3:  Activation of the MAPKs through UV or stress related signals causing the 
transcription of JNK related genes.  Image adapted from [54]. 
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